Table 4.

Prognostic Factors for PFS Based on Univariate Analyses and Final Multivariate Model.

Factors	Univariate Analysis					Multivariate Analysis
	Total No.	No. Events	5-Year PFS (%)	Cumulative Hazard Ratio	Log-rank, P	P	Hazard Ratio (95% CI)
Age, y
≤65	124	61	44.86	1			1
>65	47	26	13.26	2.52	.049	.471	1.24 (0.70–2.19)
Sex
Male	106	54	37.84	1
Female	65	33	38.33	0.99	.981
ECOG
0, 1	139	65	42.77	1			1
2, 3	32	22	12.23	2.47	.0002	.048	1.93 (1.02–4.07)
Genetic status
Exon 9	22	18	18.70	1			1
Exon 11	94	50	34.18	0.64		.042	0.52 (0.28–0.98)
Wild type	13	4	64.10	0.27	.003	.036	0.29 (0.09–0.92)
Sum of tumor, cm
<11.5	77	32	41.18	1			1
≥11.5	80	48	32.67	1.26	.043	.004	2.18 (1.29–3.69)
WBC, x109/L
<10	136	70	38.30	1
≥10	19	10	24.56	1.46	.706
RBC, x109/L
<4.0	58	32	28.61	1
≥4.0	76	40	30.91	0.94	.915
Hemoglobin, g/dl
<12	93	50	31.17	1
≥12	61	29	41.03	0.76	.328
HCT, %
<36	71	41	23.79	1
≥36	64	32	36.64	0.70	.391
MCV, fl
<80	23	11	29.11	1
≥80	111	61	29.67	0.98	.792
Platelet, x109/L
<150	19	10	33.39	1
≥150	136	70	34.99	0.96	.922
Albumin, g/dl
<3.5	35	20	35.56	1
≥3.5	79	38	34.36	1.03	.316
INR
≤1.2	70	38	20.94	1
>1.2	10	6	35.00	0.67	.832
BUN, mg/dl
≤21	110	58	30.32	1
>21	14	8	40.41	0.76	.820
Creatinine, mg/dl
≤1.03	99	54	32.69	1
>1.03	52	25	37.34	0.88	.239
AST, U/L
<34	114	56	37.50	1
≥34	27	15	32.75	1.14	.563
ALT, U/L
<36	115	59	32.04	1
≥36	22	13	34.34	0.94	.245
ALK-P, U/L
<94	98	45	39.95	1
≥94	26	17	31.33	1.27	.310
Bil, T
<1.0	94	49	37.72	1
≥1.0	25	10	34.52	1.09	.458
Sodium, mEq/L
<139	55	32	23.13	1
>139	48	24	43.80	0.56	.818
Potassium, mEq/L
≤4	58	32	25.60	1
>4	45	24	33.15	0.81	.819
Response
CR/PR	98	41	44.53	1			1
SD	51	24	41.91	1.07		.083	1.75 (0.93–3.29)
PD	22	22	0.00	NA	<.0001	<.0001	186.88 (37.15–940.09)

95% CI indicates 95% confidence interval; ALK-P, alkaline phosphatase; ALT, alanine ainotransferase; AST, aspartate aminotransferase; Bil, T, total bilirubin; BUN, blood urea nitrogen; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HCT, hematocrit; INR, international normalized ratio; PD, progressive disease; PFS, progression free survival; PR, partial response; SD, stable disease; y, years.